The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments ...

Using the same discretized logic, let’s consider LLY stock. In the trailing 10 weeks, the market voted to buy LLY six times ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to bring down prices in the United States after weeks of pressure from the Trump ...

Some would say Eli Lilly just had its Novo Nordisk moment. Analysts mostly agree that the selloff in Lilly shares after the ...

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...